Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
NCT02389543 · Karyopharm Therapeutics Inc · PHASE1/PHASE2 · withdrawn · last registry update 2023-01-26 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated this trial and added a Lenalidomide arm to KCP-330-017” | Open Targets' class: another study | Registry record, Karyopharm Therapeutics Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XPO1 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-06Phase 3 first posted: AbbVie, Etentamig + Carfilzomib (NCT06158841)
- 2023-10-25Results posted on the registry: Weill Medical College of Cornell University, Selinexor + Clarithromycin (NCT04843579)
- 2023-10-25Also stopped (terminated): Weill Medical College of Cornell University, Selinexor + Clarithromycin (NCT04843579)
- 2023-06-15Results posted on the registry: Antengene Corporation, ATG-010 (NCT03944057)
- 2023-01-26Also stopped (withdrawn): Karyopharm Therapeutics Inc, Selinexor + Placebo (for selinexor) (NCT02628704)
- 2023-01-09Phase 3 first posted: Universitätsklinikum Hamburg-Eppendorf, Allogeneic Stem Cells + carfilzomib/lenalidomide/dexamethasone (KRD) (NCT05675319)
- 2022-05-04Also stopped (withdrawn): Tulane University School of Medicine, Elotuzumab, Selinexor, and Dexamethasone (ESd) (NCT05170789)
- 2022-05-03Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Selinexor + Melphalan (NCT02780609)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision